Targeting a new GPCR to treat glioblastomas

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$291,952.00
Award Year:
2012
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA165452-01A1
Award Id:
n/a
Agency Tracking Number:
R43CA165452
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
720 Broadway, Suite 411, SEATTLE, WA, -
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
967716528
Principal Investigator:
ERIC HORNE
(206) 579-7844
stellathera.eh@gmail.com
Business Contact:
NEPHI STELLA
(206) 579-7844
stellathera@gmail.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): There is an urgent need for novel therapies to treat malignant astrocytomas, the most common and aggressive primary tumor of the nervous system. Using current standard of care, patients diagnosed with these tumors havean average life expectancy of 18 months and there is no effective treatment available. The laboratory of Dr. Nephi Stella recently discovered a new subclass of indole compounds that activate GPR124, a GPCR with established relevance in tumor pathogenesis.These indoles demonstrate efficacy in both in vitro and in vivo rodent models of malignant astrocytomas. Notably, the therapeutic effective doses of indoles do not produce overt toxicity in mice. The goal of Stella Therapeutics is to develop drugs that target GPR124 and efficiently treat malignant astrocytomas with minimal side-effects. In this proof-of-concept work, we will: Aim 1: Validate an in vitro assay tha measures the potency of GPR124 agonists in human astrocytoma cells. Use this assay to screen 40analogues of NMP-192 (EC50 = 54 nM). Aim 2: Select the 2 most promising compounds and establish their pharmacokinetic and acute toxicity profiles in mice, as well as measure their in vivo efficacy in a xenograft mouse model of malignant astrocytomas. Bythe end of this Phase I SBIR, Stella Therapeutics will have developed a lead compound that activates GPR124, exhibits in vivo efficacy and induces minimal side effects. The resulting phase II SBIR will further optimize the drug-like properties of the leadcompound by using state-of-the-art medicinal chemistry and chemo-informatics. We will systematically measures their therapeutic efficacy and side effects to establish a therapeutic index. Stella Therapeutics is dedicated to developing and patenting novel drug-based therapies to treat malignant tumors. PUBLIC HEALTH RELEVANCE: There is an urgent need for novel therapies to treat malignant astrocytomas, the most common and aggressive primary tumor of the nervous system. This phase I SBIR outlines a strategy to develop a new therapeutic approach to treat these tumors. By combining the strength of several state-of-the-art approaches in drugs development, we will develop small molecules that activate a novel therapeutic target expressed by malignant astrocytomas. Stella Therapeutics is dedicated to developing and patenting novel drug-based therapies to treat malignant tumors.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government